Glenmark to commercialize BeiGene’s oncology drugs in India

Sub: Science and tech

Sec: Health

Tags: Tislelizumab, Zanubrutinib

Context:

Drugmaker Glenmark has entered into an exclusive marketing and distribution agreement with BeiGene to register and commercialize the latter’s oncology medicines Tislelizumab and Zanubrutinib in India.

More on news:

Glenmark will be responsible for locally required development, registration and distribution providing access to BeiGene’s oncology medicines for cancer patients across India.

About the drugs:

Tislelizumab:

Tislelizumab is a novel anti-programmed cell death protein 1 (PD-1) monoclonal antibody for the treatment of advanced or metastatic esophageal squamous cell carcinoma and broad development for the treatment of various types of cancers.
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.

Zanubrutinib:

Zanubrutinib is a BTK inhibitor approved for treatment of certain hematological malignancies, with results of several studies reinforcing its favorable efficacy and safety profile.
Zanubrutinib is a chemotherapy drug used to treat certain types of B-cell cancers.
These cancers affect B-lymphocytes, a type of white blood cell that helps you fight off infection.
They occur when your body makes too many abnormal B-cells.